Ascletis Announces Positive Topline Results of U.S. Phase Ib Multiple Ascending Dose Study of Small Molecule Oral GLP-1R Agonist ASC30 and Submission of 13-week Phase IIa Study Protocol to FDA

Ascletis Announces Positive Topline Results of U.S. Phase Ib Multiple Ascending Dose Study of Small Molecule Oral GLP-1R Agonist ASC30 and Submission of 13-week Phase IIa Study Protocol to FDA

- ASC30 oral once-daily tablet demonstrated a 6.5% placebo-adjusted mean body weight reduction from baseline after four-week treatment using weekly doses with titrations of 2 mg, 10 mg, 20 mg , and 40 mg doses. - ASC30 oral once-daily tablet also...

Cheche Group Announces Partnership with Jetour Auto

Cheche Group Announces Partnership with Jetour Auto

BEIJING, April 22, 2025 /PRNewswire/ -- Cheche Group Inc. (NASDAQ: CCG) ("Cheche" or the "Company"), China's leading auto insurance technology platform, today announced that it has entered into a partnership with Wuhu Jetour Automobile Sales Company...

ENGWE Announces Global Pricing Adjustment Amid Tariff Challenges, Strengthens Long-Term Brand Strategy

ENGWE Announces Global Pricing Adjustment Amid Tariff Challenges, Strengthens Long-Term Brand Strategy

NEW YORK, April 22, 2025 /PRNewswire/ -- ENGWE, a leading brand in the electric bike field, has announced a strategic adjustment to its omnichannel pricing structure, effective May 2025. This change will apply across the entire product line in...

DXC Announces AI Workbench; Ferrovial to Serve as Anchor Client

DXC Announces AI Workbench; Ferrovial to Serve as Anchor Client

DXC's AI Workbench combines industry and AI expertise to scale outcomes for global customers ASHBURN, Va., April 22, 2025 /PRNewswire/ -- DXC Technology (NYSE: DXC), a leading Fortune 500 global technology services provider, introduced today DXC AI...

Onward Therapeutics Announces IMPD Approval for Its Subsidiary Emercell to Start Clinical Investigation of Allogeneic NK Cell Therapy OT-C001 in Combination with Rituximab

Onward Therapeutics Announces IMPD Approval for Its Subsidiary Emercell to Start Clinical Investigation of Allogeneic NK Cell Therapy OT-C001 in Combination with Rituximab

EPALINGES, Switzerland and PARIS, April 22, 2025 /PRNewswire/ -- Onward Therapeutics SA, a biotechnology company dedicated to advancing innovative cancer immunotherapies, announced that its subsidiary, Emercell SAS, has received Investigational...

Campaign Asia-Pacific announces Campaign360 2025: A premier event for marketing leaders

Campaign Asia-Pacific announces Campaign360 2025: A premier event for marketing leaders

HONG KONG, April 22, 2025 /PRNewswire/ -- Campaign Asia-Pacific, owned by Haymarket Media Limited, is thrilled to announce the return of its flagship event, Campaign360, which will take place on May 27-28, 2025, at the iconic Marina Bay Sands in...

Thunes Expands Direct Global Network with Business Payments Solution

Thunes Expands Direct Global Network with Business Payments Solution

Thunes to provide its Members faster, transparent international business payments, with access to local ACH in over 50 countries and USD wire transfers to over 170 countries. SINGAPORE, April 22, 2025 /PRNewswire/ -- Thunes, the Smart Superhighway...

LightInTheBox Announces Positive Customer Feedback and Return to Profitability with New Direct-to-Consumer Brand

LightInTheBox Announces Positive Customer Feedback and Return to Profitability with New Direct-to-Consumer Brand

SINGAPORE, April 21, 2025 /PRNewswire/ -- LightInTheBox Holding Co., Ltd. (NYSE: LITB) ("LightInTheBox" or the "Company"), a global online retail company, today announced that it has received positive feedback from customer surveys regarding one of...

Rona Therapeutics Announces NMPA Approval of IND Application for RN1871, a Novel Angiotensinogen (AGT)-Targeting siRNA Drug for Hypertension

Rona Therapeutics Announces NMPA Approval of IND Application for RN1871, a Novel Angiotensinogen (AGT)-Targeting siRNA Drug for Hypertension

SHANGHAI, April 21, 2025 /PRNewswire/ -- Rona Therapeutics, a biotechnology company pioneering innovative RNA-targeted therapies, announced that the Investigational New Drug (IND) application for RN1871, a small interfering RNA (siRNA) drug...

Recurrent Energy Announces Successful Operation of 127 MW Solar Project in Louisiana

Recurrent Energy Announces Successful Operation of 127 MW Solar Project in Louisiana

KITCHENER, ON, April 21, 2025 /PRNewswire/ -- Recurrent Energy, a subsidiary of Canadian Solar Inc. ("Canadian Solar") (NASDAQ: CSIQ), and a global developer, owner, and operator of solar and energy storage assets, held a tour and ribbon cutting...

  • 1
  • ...
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • ...
  • 84
  • menu
    menu